Skip to content

Study · Non-randomized trial · n = 131 · 2010

5 results

Analysis of testosterone suppression in men receiving histrelin, a novel GnRH agonist for the treatment of prostate cancer.

Djavan B, Schlegel P, Salomon G, Eckersberger E, Sadri H, Graefen M

The Canadian journal of urology1 Aug 2010Cited by 5 (Europe PMC)

PMID20735905 (opens in a new tab)PepBankPUB-20735905
Publisher pageAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer receiving histrelin, all patients had testosterone at or below 50 ng/dL between weeks 4 and 52.

    In plain wordsIn men with prostate cancer receiving histrelin, all had testosterone at or below 50 ng/dL between weeks 4 and 52.

    Peptide
    Histrelin
    Outcome
    DecreaseTestosterone at or below castration threshold
    Study

    n = 131

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    Testosterone suppression (testosterone < or = 50 ng/dL) was measured in all patients between weeks 4 and 52; 88% of patients had a continuous testosterone level under 20 ng/dL.
    2 context sentences
    Summary · context
    One hundred thirty-one patients with histologically confirmed prostate cancer and normal testosterone levels were prospectively evaluated over 1 year.
    Summary · context
    Androgen deprivation therapy was performed using a once yearly implant of the GnRH agonist histrelin.
  2. 02HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer receiving histrelin, 88% had continuous testosterone below 20 ng/dL.

    In plain wordsIn men with prostate cancer receiving histrelin, 88% had continuous testosterone below 20 ng/dL.

    Peptide
    Histrelin
    Outcome
    Not applicableContinuous testosterone below 20 ng/dL
    Study

    n = 131

    Outcome group
    Sex hormones and fertility · Endocrine and hormones
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Patients with continuous testosterone level under 20 ng/dL
    88%
    131 men treated with histrelin implant, over 1 year

    Source sentences

    Summary
    Testosterone suppression (testosterone < or = 50 ng/dL) was measured in all patients between weeks 4 and 52; 88% of patients had a continuous testosterone level under 20 ng/dL.
    2 context sentences
    Summary · context
    One hundred thirty-one patients with histologically confirmed prostate cancer and normal testosterone levels were prospectively evaluated over 1 year.
    Summary · context
    Androgen deprivation therapy was performed using a once yearly implant of the GnRH agonist histrelin.
  3. 03HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer receiving histrelin, PSA decreased significantly within the first 2 weeks compared with baseline.

    In plain wordsIn men with prostate cancer receiving histrelin, PSA decreased within the first 2 weeks compared with baseline.

    Peptide
    Histrelin
    Outcome
    DecreasePSA decrease from baseline
    Study

    n = 131

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated

    Source sentences

    Summary
    The PSA level in the total population decreased significantly within the first 2 weeks compared with baseline, and after 52 weeks the median PSA level of the total population was 0.2 ng/mL.
    2 context sentences
    Summary · context
    One hundred thirty-one patients with histologically confirmed prostate cancer and normal testosterone levels were prospectively evaluated over 1 year.
    Summary · context
    Androgen deprivation therapy was performed using a once yearly implant of the GnRH agonist histrelin.
  4. 04HumanNon-randomized trialEfficacy outcome

    In men with prostate cancer receiving histrelin, median PSA was 0.2 ng/mL after 52 weeks.

    In plain wordsIn men with prostate cancer receiving histrelin, median PSA was 0.2 ng/mL after 52 weeks.

    Peptide
    Histrelin
    Outcome
    Not applicableMedian PSA at 52 weeks
    Study

    n = 131

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Measurements

    Median PSA at 52 weeks
    0.2 ng/mL
    total population

    Source sentences

    Summary
    The PSA level in the total population decreased significantly within the first 2 weeks compared with baseline, and after 52 weeks the median PSA level of the total population was 0.2 ng/mL.
    2 context sentences
    Summary · context
    One hundred thirty-one patients with histologically confirmed prostate cancer and normal testosterone levels were prospectively evaluated over 1 year.
    Summary · context
    Androgen deprivation therapy was performed using a once yearly implant of the GnRH agonist histrelin.
  5. 05HumanObservational studyEfficacy outcome

    In men with prostate cancer receiving histrelin, PSA responses correlated with clinical risk distribution and PSA decreased in all three risk groups.

    In plain wordsIn men with prostate cancer receiving histrelin, PSA decreased in all three risk groups and responses correlated with clinical risk.

    Peptide
    Histrelin
    Outcome
    DecreasePSA response by risk group
    Study

    n = 131

    Outcome group
    Tumor growth · Cancer
    Studied dose
    Dose not stated · 1 yearAs given in this study (human).

    Source sentences

    Summary
    PSA responses were grouped into three typical therapeutic outcomes and correlated with the clinical risk distribution, and levels were lowered in all three risk groups.
    2 context sentences
    Summary · context
    One hundred thirty-one patients with histologically confirmed prostate cancer and normal testosterone levels were prospectively evaluated over 1 year.
    Summary · context
    Androgen deprivation therapy was performed using a once yearly implant of the GnRH agonist histrelin.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

Publication types

PepBank is a research reference. Talk to a doctor before you use any peptide.